Improved sales and marketing contributed to Aspyra Inc. narrowing its net loss for the third quarter when compared with the previous year. The Calabasas-based manufacturer of clinical and diagnostic information systems for the healthcare industry reported a net loss of $719,462 or $.06 per diluted share, on revenues of $2.2 million for the quarter ending Sept. 30. For the same period in 2007, the company had a net loss of $1.5 million, or $0.13 per diluted share, on revenues of $2.9 million. Cost reductions have improved the company’s financial performance, said interim CEO James Zierick. “Our pipeline of new sales opportunities continues to grow as a result of our improved sales and marketing execution, however; we are seeing buyers delay investments in new systems due to their uncertainty about the overall economic environment,” Zierick said. Shares of Aspyra closed down at $0.23.
